Evidence map›Paper›PMID 25323588›Full record

ReviewCell death and differentiation2015

Hexokinase II integrates energy metabolism and cellular protection: Akting on mitochondria and TORCing to autophagy.

D J Roberts, S Miyamoto

Erratum issuedOpen access · bronzeAbstract readReview
In one paragraph

Review in Cell death and differentiation, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 255 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
255citing papers in PubMed, 1 pooled it
8.0field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

255 citing papers in PubMed, 1 synthesis or guideline pooled it, 497 citations in OpenAlex.

  1. Guideline
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Type 2 diabetes mellitus.Nature reviews. Disease primers · 2026
    Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review

195 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

D J RobertsDepartment of Pharmacology, University of California, San Diego, 9500 Gilman Drive, La Jolla, CA, USA.
S MiyamotoDepartment of Pharmacology, University of California, San Diego, 9500 Gilman Drive, La Jolla, CA, USA.
University of California, San Diego · US

Funding

Mitochondrial Protection by Hexokinase-II and Akt in the HeartR01HL097037 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI MIYAMOTO, SHIGEKI · 2009 to 2013
$1.9M
Hexokinase-II protects the heart against ischemia through regulation of autophagyR56HL097037 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI MIYAMOTO, SHIGEKI · 2015 to 2015
$388k
NHLBI NIH HHS HL097037NHLBI NIH HHS R01 HL097037NHLBI NIH HHS R56 HL097037
6 · The paper itself

Abstract

Accumulating evidence reveals that metabolic and cell survival pathways are closely related, sharing common signaling molecules. Hexokinase catalyzes the phosphorylation of glucose, the rate-limiting first step of glycolysis. Hexokinase II (HK-II) is a predominant isoform in insulin-sensitive tissues such as heart, skeletal muscle, and adipose tissues. It is also upregulated in many types of tumors associated with enhanced aerobic glycolysis in tumor cells, the Warburg effect. In addition to the fundamental role in glycolysis, HK-II is increasingly recognized as a component of a survival signaling nexus. This review summarizes recent advances in understanding the protective role of HK-II, controlling cellular growth, preventing mitochondrial death pathway and enhancing autophagy, with a particular focus on the interaction between HK-II and Akt/mTOR pathway to integrate metabolic status with the control of cell survival.

Indexed as

AutophagySignal TransductionAnimalsEnergy MetabolismGlycolysisHexokinaseHumansMechanistic Target of Rapamycin Complex 1MiceMitochondriaMultiprotein ComplexesPhosphorylationProto-Oncogene Proteins c-aktTOR Serine-Threonine KinasesHexokinaseMechanistic Target of Rapamycin Complex 1Multiprotein ComplexesProto-Oncogene Proteins c-aktTOR Serine-Threonine Kinases

Identifiers

PMID25323588
PMCPMC4291497
OpenAlexW2067958598

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.